Allogene (ALLO) Reiterated at Market Outperform by Citizens on Progress in Autoimmune Diseases
Tweet Send to a Friend
(Updated - September 15, 2026 9:19 AM EDT)
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




